Aura Biosciences, Inc. (AURA) dividends
AURA on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Aura Biosciences, Inc. dividend: key facts
Own Aura Biosciences, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next AURA dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- 3 Best Stocks Under $10 to Buy for 80%+ Upside, According to Analysts11 Nov 2026 · TipRanks
Several stocks trading below $10 have caught analystsâ attention. Using TipRanksâ database, we identified VNET Group ($VNET), SoundHound AI ($SOUN), and Aura Biosciences ($AURA), with average price ta...
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights9 Nov 2026 · GlobeNewsWire
Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capa...
- Aura Biosciences to Participate in Upcoming Investor Conference4 Nov 2026 · GlobeNewsWire
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with...
- Aura Biosciences files $500M mixed securities shelf15 Sep 2026 · TheFly
16:21 EDT Aura Biosciences (AURA) files $500M mixed securities shelf
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)15 Sep 2026 · GlobeNewsWire
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (âAuraâ or the âCompanyâ), a clinical-stage biotechnology company developing a potentially transformative first-in-clas...
- Aura Biosciences price target lowered to $18 from $24 at H.C. Wainwright16 Aug 2026 · TheFly
H.C. Wainwright lowered the firmâs price target on Aura Biosciences (AURA) to $18 from $24 and keeps a Buy rating on the shares. Aura is scaling back investment in itsâ¦
- Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors17 Jul 2026 · GlobeNewsWire
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ funct...
- Aura Biosciences completes enrollment in belzupacap sarotalocan trial17 Jun 2026 · TheFly
Aura Biosciences (AURA) announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan as a frontline treatment for patients with early choroidal melanoma...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.